Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model
HXB-319 effectively controls inflammation and prevents tissue damage in pristine-induced DAH, highlighting its therapeutic potential for autoimmune inflammatory diseases.
Authors
- Nora G. Singer (ORCID: https://orcid.org/0000-0001-7041-723X)
- Kristin B. Highland (ORCID: https://orcid.org/0000-0001-5072-0725)
- Jane Reese‐Koc
- Steven N. Emancipator
- Scott F. Sieg (ORCID: https://orcid.org/0000-0002-1769-8682)
- Brian Clagett (ORCID: https://orcid.org/0009-0006-4046-125X)
- Hülya Bükülmez (ORCID: https://orcid.org/0000-0002-2256-9068)
- Adrienne T. Dennis
- Mark R. Chance (ORCID: https://orcid.org/0000-0002-2991-6405)
- Sarah Kleinsorge-Block
- Rodrigo Somoza-Palacios
Institutions
- Cleveland Clinic (US)
- MetroHealth Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Stem Cells
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/stmcls/sxae078
- Citations
- 2
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Case Western Reserve University
- Lastentautien Tutkimussäätiö
- National Institutes of Health
- Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University
- National Center for Advancing Translational Sciences